<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360152</url>
  </required_header>
  <id_info>
    <org_study_id>06-0530 / 201109077</org_study_id>
    <nct_id>NCT00360152</nct_id>
  </id_info>
  <brief_title>Testing of Different Methods for Determining Whether Breast Cancer Has Spread to the Lymph Nodes</brief_title>
  <official_title>Minimally Invasive Staging of the Axilla in Breast Cancer: A Pilot Study to Assess the Feasibility of Axillary Ultrasound, Fine Needle Aspiration Biopsy and Molecular Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society for Surgical Oncologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sysmex America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sentinel lymph node biopsy (SLNB) has recently emerged as a less invasive alternative to
      axillary lymph node dissection (ALND) in the treatment of breast cancer. However, SLNB has a
      number of limitations, and we believe that alternative strategies for staging of the axilla
      should be explored. The hypothesis of this proposal is that the combination of preoperative
      high-resolution axillary ultrasound (AUS), fine needle aspiration biopsy (FNAB), and
      molecular analysis using real-time reverse transcription-polymerase chain reaction (RT-PCR)
      represents a viable, minimally invasive alternative to SLNB. We propose a prospective cohort
      study to rigorously assess the diagnostic accuracy of molecular analysis of AUS-FNAB
      specimens. The primary endpoint of this study is to determine the feasibility of AUS-FNAB and
      real-time RT-PCR to predict the pathologic status of the axilla in a proof-of-principle
      study. In the short term, validation of this innovative strategy is likely to reduce the
      number of sentinel node procedures. In the long term, we believe that AUS-FNAB may ultimately
      replace SLNB.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the sensitivity of AUS and real-time RT-PCR/RT-LAMP to predict the pathologic status of the axilla in breast cancer patients</measure>
    <time_frame>At the time of ultrasound guidance and during definitive surgery for cancer</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the feasibility of AUS, FNAB, and RT-PCR/RT-LAMP as an alternative to SLNB for axillary staging of breast cancer patients</measure>
    <time_frame>At the time of ultrasound guidance and during definitive surgery for cancer</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Define baseline gene expression levels in lymph nodes by RT-PCR/RT-LAMP in patients with no evidence of malignancy undergoing procedures under general anesthesia</measure>
    <time_frame>At the time of procedure under general anesthesia</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Positive Axillary Ultrasound</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Positive Axillary Ultrasound -&gt; Fine Needle Aspiration Biopsy -&gt; Cytopathology and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) -&gt; Positive Cyto=Axillary Lymph Node Dissection, Negative Cyto=Sentinel Lymph Node Biopsy -&gt; Pathology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Axillary Ultrasound</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Negative Axillary Ultrasound -&gt; Sentinel Lymph Node Biopsy/Fine Needle Aspiration Biopsy -&gt; Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Pathology</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fine needle aspiration biopsy (FNAB)</intervention_name>
    <arm_group_label>Positive Axillary Ultrasound</arm_group_label>
    <arm_group_label>Negative Axillary Ultrasound</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel Lymph Node Biopsy</intervention_name>
    <arm_group_label>Positive Axillary Ultrasound</arm_group_label>
    <arm_group_label>Negative Axillary Ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients, aged 18 and over.

          -  Patients must be newly diagnosed with clinical stage I or II breast cancer and be
             eligible for breast surgery and core breast biopsy of their proven breast carcinoma.

        Exclusion Criteria:

          -  Inability to give informed consent

          -  Contraindications for breast surgery or biopsy

        Patients with no evidence of malignancy scheduled to undergo procedures under general
        anesthesia must fulfill the following eligibility requirements:

          -  Female patients, aged 18 and over

          -  Patient must be scheduled to undergo a procedure under general anesthesia with access
             to lymph nodes that can be biopsied by FNA biopsy at minimal risk to the patient

          -  Patient must be willing to give informed consent

          -  Patient with no history of malignancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie A. Margenthaler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <reference>
    <citation>Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer. 1978 Mar;41(3):1170-8.</citation>
    <PMID>638961</PMID>
  </reference>
  <reference>
    <citation>Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S, Beitsch P. The sentinel node in breast cancer--a multicenter validation study. N Engl J Med. 1998 Oct 1;339(14):941-6.</citation>
    <PMID>9753708</PMID>
  </reference>
  <reference>
    <citation>McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, Vennekotter DJ, Turk PS, Tate PS, Sardi A, Cerrito PB, Edwards MJ. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000 Jul;18(13):2560-6.</citation>
    <PMID>10893287</PMID>
  </reference>
  <reference>
    <citation>Ung OA. Australasian experience and trials in sentinel lymph node biopsy: the RACS SNAC trial. Asian J Surg. 2004 Oct;27(4):284-90.</citation>
    <PMID>15564180</PMID>
  </reference>
  <reference>
    <citation>Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, Duffy SW. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005 Jul 1;23(19):4312-21.</citation>
    <PMID>15994144</PMID>
  </reference>
  <reference>
    <citation>Posther KE, Wilke LG, Giuliano AE. Sentinel lymph node dissection and the current status of American trials on breast lymphatic mapping. Semin Oncol. 2004 Jun;31(3):426-36. Review.</citation>
    <PMID>15190501</PMID>
  </reference>
  <reference>
    <citation>Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002 Aug 22;347(8):567-75.</citation>
    <PMID>12192016</PMID>
  </reference>
  <reference>
    <citation>Brancato B, Zappa M, Bricolo D, Catarzi S, Risso G, Bonardi R, Cariaggi P, Bianchin A, Bricolo P, Rosselli Del Turco M, Cataliotti L, Bianchi S, Ciatto S. Role of ultrasound-guided fine needle cytology of axillary lymph nodes in breast carcinoma staging. Radiol Med. 2004 Oct;108(4):345-55. English, Italian.</citation>
    <PMID>15525888</PMID>
  </reference>
  <reference>
    <citation>Deurloo EE, Tanis PJ, Gilhuijs KG, Muller SH, Kröger R, Peterse JL, Rutgers EJ, Valdés Olmos R, Schultze Kool LJ. Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer. 2003 May;39(8):1068-73.</citation>
    <PMID>12736105</PMID>
  </reference>
  <reference>
    <citation>Krishnamurthy S, Sneige N, Bedi DG, Edieken BS, Fornage BD, Kuerer HM, Singletary SE, Hunt KK. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer. 2002 Sep 1;95(5):982-8.</citation>
    <PMID>12209680</PMID>
  </reference>
  <reference>
    <citation>Parker SH, Dennis MA, Kaske TI. Identification of the sentinel node in patients with breast cancer. Radiol Clin North Am. 2000 Jul;38(4):809-23.</citation>
    <PMID>10943279</PMID>
  </reference>
  <reference>
    <citation>Bude RO. Does contrast-enhanced US have potential for sentinel lymph node detection? Radiology. 2004 Mar;230(3):603-4.</citation>
    <PMID>14990825</PMID>
  </reference>
  <reference>
    <citation>Goldberg BB, Merton DA, Liu JB, Thakur M, Murphy GF, Needleman L, Tornes A, Forsberg F. Sentinel lymph nodes in a swine model with melanoma: contrast-enhanced lymphatic US. Radiology. 2004 Mar;230(3):727-34.</citation>
    <PMID>14990839</PMID>
  </reference>
  <reference>
    <citation>Wisner ER, Ferrara KW, Short RE, Ottoboni TB, Gabe JD, Patel D. Sentinel node detection using contrast-enhanced power Doppler ultrasound lymphography. Invest Radiol. 2003 Jun;38(6):358-65.</citation>
    <PMID>12908703</PMID>
  </reference>
  <reference>
    <citation>Gillanders WE, Mikhitarian K, Hebert R, Mauldin PD, Palesch Y, Walters C, Urist MM, Mann GB, Doherty G, Herrmann VM, Hill AD, Eremin O, El-Sheemy M, Orr RK, Valle AA, Henderson MA, Dewitty RL, Sugg SL, Frykberg E, Yeh K, Bell RM, Metcalf JS, Elliott BM, Brothers T, Robison J, Mitas M, Cole DJ. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg. 2004 Jun;239(6):828-37; discussion 837-40.</citation>
    <PMID>15166962</PMID>
  </reference>
  <reference>
    <citation>Mikhitarian K, Gillanders WE, Almeida JS, Hebert Martin R, Varela JC, Metcalf JS, Cole DJ, Mitas M. An innovative microarray strategy identities informative molecular markers for the detection of micrometastatic breast cancer. Clin Cancer Res. 2005 May 15;11(10):3697-704.</citation>
    <PMID>15897566</PMID>
  </reference>
  <reference>
    <citation>Mitas M, Mikhitarian K, Hoover L, Lockett MA, Kelley L, Hill A, Gillanders WE, Cole DJ. Prostate-Specific Ets (PSE) factor: a novel marker for detection of metastatic breast cancer in axillary lymph nodes. Br J Cancer. 2002 Mar 18;86(6):899-904.</citation>
    <PMID>11953821</PMID>
  </reference>
  <reference>
    <citation>Mitas M, Mikhitarian K, Walters C, Baron PL, Elliott BM, Brothers TE, Robison JG, Metcalf JS, Palesch YY, Zhang Z, Gillanders WE, Cole DJ. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer. 2001 Jul 15;93(2):162-71.</citation>
    <PMID>11410861</PMID>
  </reference>
  <reference>
    <citation>Mitas M, Cole DJ, Hoover L, Fraig MM, Mikhitarian K, Block MI, Hoffman BJ, Hawes RH, Gillanders WE, Wallace MB. Real-time reverse transcription-PCR detects KS1/4 mRNA in mediastinal lymph nodes from patients with non-small cell lung cancer. Clin Chem. 2003 Feb;49(2):312-5.</citation>
    <PMID>12560358</PMID>
  </reference>
  <reference>
    <citation>Wallace MB, Block MI, Gillanders W, Ravenel J, Hoffman BJ, Reed CE, Fraig M, Cole D, Mitas M. Accurate molecular detection of non-small cell lung cancer metastases in mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. Chest. 2005 Feb;127(2):430-7.</citation>
    <PMID>15705978</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2006</study_first_submitted>
  <study_first_submitted_qc>August 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2006</study_first_posted>
  <last_update_submitted>July 2, 2013</last_update_submitted>
  <last_update_submitted_qc>July 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Axilla</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>FNA</keyword>
  <keyword>Molecular Analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

